DIAO H X, GUO Z L, ZHAN R T,et al. Investigation and Analysis on the current situation of the use of Chinese patent medicine in China[J].China Pract Med(中国实用医药),2010,5(36):14-16.
[2]
LI Z X, DUAN R. Research status and reflection of methods and tools for drug selection and evaluation in medical institutions from China[J]. Eval Anal Drug Use Hosp China(中国医院用药评价与分析),2022,22(3):257-260,264.
[3]
ZHANG Q, WANG Z F, XIE Y M,et al. Technical specification for clincal comprehensive evaluation of Chinese patent medicine[J].World Chin Med(世界中医药),2021,16(22):3394-3397,3403.
[4]
ZHAO Z G, DONG Z J, LIU J P.A Quick guideline for drug evaluation and selection in Chinese medical institutions[J].Her Med(医药导报),2020,39(11):1457-1465.
[5]
Guangdong Pharmaceutical Association. Expert consensus on statin evaluation and selection in Guangdong Province[J/OL]. Pharm Today(今日药学):1-17[2022-04-09].http://kns.cnki.net/kcms/detail/44.1650.R.20220106.1422.002.html.
[6]
SHU Y C, TIAN L, TAN X Y.Jiangsu expert consensus on the formation of evaluation index system for variety selection and clinical application of Chinese patent medicine in medical institutions[J]. J China Pharm(中国药房), 2022,33(2):129-135.
[7]
National Health Commission. Notice on carrying out drug use monitoring and clinical comprehensive evaluation[EB/OL]. [2019-04-09]. http://www.nhc.gov.cn/yaozs/pqt/201904/31149bb1845e4c019a04f30c0d69c2c9.shtml.
[8]
National Health Commission. Notice on printing and distributing the opinions on Strengthening Drug Administration in medical institutions and promoting rational drug use[EB/OL]. [2020-02-26].http://www.satcm.gov.cn/xinxifabu/shizhengyaowen/2020-02-26/13420.html.
[9]
National Medical Products Administration. Implementation Opinions on promoting the inheritance, innovation and development of traditional Chinese Medicine[EB/OL]. [2020-12-25]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/202012251 6390 6151.html.
[10]
National Health Commission. Notice on standardizing the comprehensive clinical evaluation of drugs[EB/OL]. [2021-07-28].http://wsjkw.hebei.gov.cn/zcfg2/380991.jhtml.
[11]
ZHANG H L, JIAO L W, LIANG N,et al. Construction of multi dimension and multi criteria evaluation index system for superior Chinese patent medicines based on comprehensive evaluation method[J]. J Basic Chin Med(中国中医基础医学杂志),2021,27(3):403-406.
[12]
Annual report of national adverse drug reaction monitoring(2021)[EB/OL]. [2022-03-30].https://www.cdr-adr.org.cn/tzgg_home/202203/t20220330_49585.html.
[13]
ZHAO W M, YANG Y, TIAN K. Analysis on the health technology assessment of traditional Chinese medicine[J]. Guid J Tradit Chin Med Pharm(中医药导报),2019,25(21):131-134.
[14]
QIAO J H, YANG P, DONG L,et al. The application of real world study in the safety evaluation of Chinese patent medicine after marketing[J].Chin New Drugs J(中国新药杂志),2021, 30(9):769-772.
[15]
DANG H X, LIU J, LI B,et al. The research on the value framework of Chinese patent medicine[J]. Chin New Drugs J(中国新药杂志),2021,30(11):961-970.
[16]
LI G, GUO Y B, LI W S, et al. Summary of competitiveness report on science and technology of big brand traditional Chinese medicine (2019 Edition)[J]. Mod Chin Med(中国现代中药), 2020,22(1):1-20.
[17]
DRUMMOND M F, SCULPHER M J, CLAXTON K, et al. Methods for the Economic Evaluation of Care Programms[M].4th ed.Oxford: Oxford University Press,2015:16-19.
[18]
TANG J Y. Thoughts and suggestions on registration and classification of traditional Chinese medicines[J]. China J Chin Mater Med(中国中药杂志),2020,45(16):4004-4008.
[19]
CHEN Y H, LING X, LI C X,et al. Discussion on research ideas of post-marketing clinical re-evaluation of traditional Chinese medicine[J].Chin New Drugs J(中国新药杂志),2021,30(24):2262-2267.
[20]
ZHOU Y H, SONG M X, SHEN X R,et al. The current situation of instructions regarding storage conditions of marketed Chinese patent medicines and the discussions on related problems[J].Chin New Drugs J(中国新药杂志), 2022,31(1):18-26.
[21]
QIAN P P, CAO K, ZHAO L,et al. Discussion on shelf life and in-use period of medicinal products[J].Chin J Pharmacovigil(中国药物警戒),2018,15(07):414-418.
[22]
ZENG J, YANG A D, ZHANG A J,et al. Registration management and analysis of high-quality transformation factors of traditional Chinese medicine compound preparations of ancient classic prescriptions[J].Pharmacol Clin Chin Mater Med(中药药理与临床),2020,36(3):242-254.
[23]
SONG Z, WANG Z F, WU Y,et al. Thoughts on post marketing evaluation of classic famous Chinese patent medicines based on clinical value[J]. China J Chin Mater Med(中国中药杂志),2021,46(8):1988-1993.
[24]
WANG L L, HU L F, ZHANG X D,et al.Analysis on approval of new Chinese medicine applied for investigational new drug from 2005 to 2020[J].Chin Tradit Herb Drugs(中草药),2021,52(12):3765-3774.
[25]
BAI X, ZHANG Q, WANG F,et al. On the way of writing the names of raw and processed products in traditional Chinese medicine patent applications[J]. Chin J Inf Tradit Chin Med(中国中医药信息杂志),2013,20(1):4-5.
[26]
CAO J L, LI X L, MENG F,et al.Expert consensus on clinical application of Chinese herbal medicine decoction pieces(First Edition)[J]. China J Chin Mater Med(中国中药杂志), 2020,45(13):3238-3244.
[27]
YAN J. Investigation and analysis of function and indication in 242 package inserts of Chinese patent medicine[J]. J China Pharm(中国药房),2012,23(44):4151-4153.
[28]
Ch.P VolⅠ(2020)(中国药典2020年版.一部)[S].2020.
[29]
ZHUANG J, ZHANG L P. Thoughts on the expression of the main functional items in the manual of Chinese patent medicine[J].China J Chin Mater Med(中国中药杂志),2001(7):68-71.
[30]
MENG F, LI X L.Discussion on Chinese medicine proprietary specifi cation term representation method[J].Clin J Tradit Chin Med(中医药临床杂志),2015,27(1):111-112.
[31]
CPC Central Committee and State Council. Opinions on promoting the inheritance, innovation and development of traditional Chinese Medicine[EB/OL]. [2019-10-26].http://www.gov.cn/zhengce/2019-10/26/content_5445336.htm.
2022, Vol. 57 
